Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 14/20 | 0.38 |
| ▸ | CNR1 | P21554 | 11/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20927024 | 0.90 | CHRNB2 (0.33) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL19139244 | 0.83 | CNR2 (0.40) | CNR2CNR1TRPV1 | |
| SCHEMBL19633847 | 0.83 | CNR2 (0.38) | CNR2CNR1 | |
| SCHEMBL19633737 | 0.83 | CNR2 (0.38) | CNR2CNR1 | |
| SCHEMBL23142669 | 0.81 | CNR2 (0.37) | CNR2CNR1 | |
| SCHEMBL22752268 | 0.80 | CYP11B1 (0.34) | CYP3A4 | |
| SCHEMBL19251089 | 0.76 | CHRNB2 (0.39) | CYP3A4CNR2CNR1 | |
| SCHEMBL18852713 | 0.76 | CNR2 (0.37) | CNR2CNR1 | |
| SCHEMBL18721019 | 0.76 | CNR2 (0.37) | CNR2CNR1 | |
| SCHEMBL20313082 | 0.76 | CNR2 (0.54) | KDM4ETP53CYP3A4MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | KDM4E 2335/4885TP53 1665/4885CYP3A4 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.